Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine IR OLE in Asian Adults with Partial Onset Seizures
NCT01777139Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of retigabine in focal onset seizure, sponsored by GSK. Primary endpoints: Number of Participants With Treatment Emergent (TE) Serious Adverse Events (SAEs) and Non-SAEs at 4 years, Percentage of Participants With TEAEs Leading to Study Discontinuation at 4 years and 13 more. Started Apr 2013; status: completed.
02
Drugs
retigabine
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01777139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777139.